Linked Life Data

15534487

Source:http://linkedlifedata.com/resource/pubmed/id/15534487

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2004-11-9
pubmed:abstractText
The authors investigated the in vivo anti-tumor effect of intratumoral administration of bone marrow-derived dendritic cells (DCs) after chemotherapy using an oral fluoropyrimidine anti-cancer drug TS-1, and followed by immunotherapeutic agent OK-432, in two syngeneic tumor-bearing mouse models. Both in Meth-A fibrosarcoma-bearing BALB/c mice and in SCCVII-bearing C3H/HeN mice, 1 week of oral administration of TS-1 effected partial eradication of established tumors. Intratumoral injection of DCs and OK-432 caused only slight inhibition of the tumor growth. However, TS-1 administration followed by DCs and OK-432 resulted in a marked inhibition in the tumor growth and also contributed to a greater prolongation of survival. By the injection of DCs and OK-432 after TS-1 administration, a significant infiltration of immune cells, especially CD8+ T cells, was observed. Furthermore, the cytotoxic activities of tumor-infiltrating lymphocytes and draining lymph node cells against inoculated tumor cells were significantly increased by the therapy, while activities against nonspecific target cells were not. Cytotoxic memory T cells were also induced; the main effectors were MHC class I-restricted, CD8+ T cells. The same therapy was also applied to SCCVII-bearing C3H/HeJ mice in which the Toll-like receptor (TLR) 4 is mutated and its function impaired; no immunotherapeutic effect was observed in the TLR4-deficient mouse model. These findings suggest that the local DC therapy in combination with TS-1 and OK-432 may be a useful strategy for the treatment of solid tumors, and that TLR4 signaling is involved in the success of this therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1524-9557
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
432-41
pubmed:dateRevised
2008-3-18
pubmed:meshHeading
pubmed-meshheading:15534487-Administration, Oral, pubmed-meshheading:15534487-Animals, pubmed-meshheading:15534487-Antineoplastic Agents, pubmed-meshheading:15534487-Bone Marrow Cells, pubmed-meshheading:15534487-Carcinoma, Squamous Cell, pubmed-meshheading:15534487-Cell Movement, pubmed-meshheading:15534487-Combined Modality Therapy, pubmed-meshheading:15534487-Cytotoxicity, Immunologic, pubmed-meshheading:15534487-Dendritic Cells, pubmed-meshheading:15534487-Drug Combinations, pubmed-meshheading:15534487-Female, pubmed-meshheading:15534487-Fibrosarcoma, pubmed-meshheading:15534487-Immunologic Memory, pubmed-meshheading:15534487-Immunotherapy, Adoptive, pubmed-meshheading:15534487-Lymph Nodes, pubmed-meshheading:15534487-Lymphocytes, Tumor-Infiltrating, pubmed-meshheading:15534487-Mice, pubmed-meshheading:15534487-Mouth Neoplasms, pubmed-meshheading:15534487-Neoplasms, Experimental, pubmed-meshheading:15534487-Oxonic Acid, pubmed-meshheading:15534487-Picibanil, pubmed-meshheading:15534487-Pyridines, pubmed-meshheading:15534487-Receptors, Cell Surface, pubmed-meshheading:15534487-T-Lymphocytes, Cytotoxic, pubmed-meshheading:15534487-Tegafur, pubmed-meshheading:15534487-Toll-Like Receptor 4, pubmed-meshheading:15534487-Tumor Cells, Cultured
pubmed:articleTitle
Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4.
pubmed:affiliation
Second Department of Oral and Maxillofacial Surgery, Tokushima University School of Dentistry, Tokushima, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't